Market Place
Sourcing Support
Flare Therapeutics Partners with Roche to Target Transcription Factors
12 Nov 2024 //
PR NEWSWIRE
Flare Therapeutics Appoints Douglas Manion as CEO
23 Apr 2024 //
PR NEWSWIRE
Flare Therapeutics Presents PPARG-Derived Immune Patterns at AACR
10 Apr 2024 //
PR NEWSWIRE
Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Trial
26 Jan 2024 //
PR NEWSWIRE
Flare Therapeutics Presents Translational Data in Support of Lead Asset FX-909
03 Nov 2023 //
PR NEWSWIRE
Flare to Present Data in Support of Candidate FX-909`s Phase 1 Development
31 Oct 2023 //
PR NEWSWIRE
Flare Therapeutics Announces First Patients Dosed in Phase 1 Study of FX-909
19 Oct 2023 //
PR NEWSWIRE
Flare Therapeutics Presents Urothelial Cancer Supporting Lead Asset FX-909
13 Oct 2023 //
PR NEWSWIRE
Flare Therapeutics to Present Biomarker Data for Clinical Candidate FX-909
04 Oct 2023 //
PR NEWSWIRE
Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909
17 Apr 2023 //
PR NEWSWIRE
Caris Life, Flare Therapeutics Enter Strategic Preferred Portfolio Partnership
17 Apr 2023 //
CONTRACT PHARMA
Flare Further Strengthens Leadership Team with Key Executive Appointments
30 Mar 2023 //
PR NEWSWIRE
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
22 Mar 2023 //
PR NEWSWIRE
Flare fires up with $123M series B and 3 Big Pharmas in tow
22 Mar 2023 //
FIERCE BIOTECH
Flare to Present Overview of Clinical Candidate FX-909 at AACR Annual Meeting
14 Mar 2023 //
BUSINESSWIRE
Flare Therapeutics to Present at Guggenheim Healthcare Talks 2023 Oncology Day
02 Feb 2023 //
BUSINESSWIRE
Flare Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
21 Nov 2022 //
BUSINESSWIRE
Flare Therapeutics Presents Real-World Data in Metastatic Urothelial Cancer
27 Oct 2022 //
BUSINESSWIRE
Flare Therapeutics Presents Data that Show Potential of Novel PPARG Inhibitors
26 Oct 2022 //
BUSINESSWIRE
Flare Therapeutics Appoints Amit Rakhit, M.D. as President and CEO
25 Jul 2022 //
BUSINESSWIRE
Flare Therapeutics to Present at the Bank of America Securities 2022 Conference
05 May 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.